SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's Laboratories targeting to triple reach to 1.5 billion patients by 2030

07 Jul 2022 Evaluate

Dr. Reddy's Laboratories is targeting to triple its reach to 1.5 billion patients by 2030 as part of its sustainability goals. Under its sustainability goals for the next decade, it is making its products accessible and affordable for patients and 25 per cent of new launches to be first to market by 2027.

Besides, by 2030 the company will use 100 per cent renewable power and it will also be carbon-neutral in direct emissions, while it is targeting 12.5 per cent reduction in indirect carbon emissions.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Labs. Share Price

1406.75 56.75 (4.20%)
29-Jun-2026 10:44 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1889.70
Dr. Reddys Labs. 1406.75
Cipla 1477.00
Zydus Lifesciences 1116.95
Lupin 2400.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: